Medical World News

[Eli's Gone]

Medizone International Successfully Completes Third Round of AsepticSure(TM) Test Program

SAN FRANCISCO, Jan. 5 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC:MZEI.OB) (BULLETIN BOARD: MZEI.OB) announces that its third round of testing and data logging for the enhanced AsepticSure(TM) technology is now complete. Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial "kill" across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis. Significantly, these results have been replicated on more than a single surface material. "This latest round of laboratory testing has confirmed beyond any reasonable doubt that our enhanced AsepticSure(TM) technology can reliably achieve sterilization standards for virtually any bacterial contaminant found in a hospital setting," stated Dr. Michael Shannon, Medizone's Director of Medical Affairs

In related news, Medizone's full scale prototype unit has been completed and demonstrated in "dry" runs (bacteria free) that it can reach both the charge time and saturation requirements of its design criteria. The ability to replicate the exact atmosphere of the laboratory test unit in a full sized room is considered a crucial step in achieving the same 6 log bactericidal action in hospital settings

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Mock-up trials are scheduled to begin in January for both public (hospital) and government (bio-terrorism countermeasures) applications

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development
, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission

Investor Relations: 415-868-0300 / web site: http://www.medizoneint.com/

E-mail: operations @ medizoneint.com

DATASOURCE: Medizone International, Inc

CONTACT: Investor Relations of Medizone International, [phone],

operations @ medizoneint.com

Web Site: http://www.medizoneint.com/